Want to see NMTC full AI Analyst Report?
Top Page
NeuroOne Medical Technologies
(NASDAQ:NMTC)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▼(-30.56% Downside)
Action:Reiterated
Date:08/29/26
The score is held back primarily by weak financial performance—deep operating losses, significant cash burn, and a shrinking equity cushion—despite rapid revenue growth and low debt. Technicals are also unfavorable with the stock below major moving averages and negative MACD. Offsetting factors include reiterated FY2026 growth guidance and operational milestones, plus positive product/program progress in recent updates, but near-term liquidity and execution timing risks remain prominent.
Positive Factors
Strong product revenue growth
Rapid growth in product revenue indicates increasing clinical adoption of NeuroOne’s devices and expanding commercial traction. Sustained procedure growth could improve operating leverage as the company scales its hospital and distributor relationships.
Negative Factors
Persistent operating losses
Deep losses show that revenue growth has not yet produced sufficient scale to cover operating expenses. Continued deficits could constrain investment capacity and require additional financing before the business reaches sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong product revenue growth
Rapid growth in product revenue indicates increasing clinical adoption of NeuroOne’s devices and expanding commercial traction. Sustained procedure growth could improve operating leverage as the company scales its hospital and distributor relationships.
Read all positive factors
NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.75M
Dividend YieldN/A
Average Volume (3M)551.58K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-1.67%
EPS Growth7.34%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.91
Shares Outstanding9,105,763
10 Day Avg. Volume1,512,299
30 Day Avg. Volume551,580
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.27Price Target Upside236.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$9.53M
NeuroOne Medical Technologies Business Overview & Revenue Model
Company Description
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse n...
How the Company Makes Money
NeuroOne makes money primarily by selling medical devices to hospitals and healthcare providers and/or through distribution channels. Its core revenue stream is product revenue from its thin-film electrode/lead offerings (including sEEG-related pr...
NeuroOne Medical Technologies Earnings Call Summary
Earnings Call Date:Aug 19, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Dec 16, 2026
Earnings Call Sentiment Neutral
The call delivered strong operational and clinical progress — including double-digit revenue growth (+16% YoY), 43% growth in orders, improved gross margins (+6.0 percentage points), ISO 13485 certification, and meaningful advances across product lines (OneRF, Trigeminal, StereoCED, BVNA). However, these positives are balanced by material near-term challenges: manufacturing lead times and backlog that constrain revenue recognition, rising operating expenses and widening net loss, and a significant decline in cash and working capital that creates liquidity pressure. Management has mitigation plans (second manufacturing site, ATM raises, supply acceleration) and clear clinical/regulatory milestones, but the financial and execution risks temper the upside from operational wins.Positive Updates
Product Revenue Growth
Product revenue for OneRF grew 16% year-over-year to $2.0M in Q3 FY2026 (from $1.7M in Q3 FY2025).
Negative Updates
Manufacturing Delays and Backlog Risk
Supplier lead times of up to ~6 months and manufacturing capacity constraints created a backlog ($1.7M as of June 30, 2026), limiting the company's ability to fully convert $11.2M in orders into recognized revenue this fiscal year; management expects to address backlog by end of calendar Q4 2026 and bring a second, larger manufacturing site online in early 2027.
Read all updates
Q3-2026 Updates
Positive
Negative
Product Revenue Growth
Product revenue for OneRF grew 16% year-over-year to $2.0M in Q3 FY2026 (from $1.7M in Q3 FY2025).
Read all positive updates
Company Guidance
Guidance for fiscal 2026 reiterated expected aggregate product orders of approximately $11.2 million and recognized revenue of $9.2–$10.5 million (timing-dependent); Q3 product revenue was $2.0M (up 16% YoY from $1.7M) with $2.7M of orders in the quarter (up 43% YoY) and a $1.7M backlog as of June 30, 2026 that management expects to address by the end of calendar Q4 2026 through supplier acceleration and qualification of a second, larger manufacturing site expected in early 2027. Gross margin expanded to 59.9% (product gross profit $1.2M vs 53.9% a year ago), total operating expenses were $3.6M (R&D $1.4M; SG&A $2.2M), net loss was $2.0M ($0.23 basic / $0.28 diluted) versus $1.5M ($0.19 / $0.22) prior-year, cash and cash equivalents were $2.0M (vs $6.6M on 9/30/25) with $1.1M AR expected to convert in Q4, working capital $3.7M (vs $7.9M), no debt, and $1.4M raised via ATM in 2026 ($0.4M in Q3; $1.0M on July 13 via 400,346 shares); strategic milestones/timing include ISO 13485 certification enabling international expansion, StereoCED aimed for investigational human studies by end-September 2026, and a BVNA 510(k) submission targeted in H2 2027, while a lead investor increased ownership from 7.4% to 12.5%.NeuroOne Medical Technologies Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.00M | 12.10M | 3.45M | 1.95M | 171.17K | 178.15K |
| Gross Profit | 5.57M | 8.14M | 1.08M | 456.52K | -70.79K | -97.75K |
| EBITDA | -6.91M | -3.01M | -11.84M | -11.66M | -9.88M | -9.80M |
| Net Income | -7.15M | -3.61M | -12.32M | -11.86M | -10.00M | -9.95M |
Balance Sheet | ||||||
| Total Assets | 6.19M | 10.79M | 5.37M | 8.10M | 12.82M | 7.94M |
| Cash, Cash Equivalents and Short-Term Investments | 2.05M | 6.57M | 1.46M | 5.32M | 11.14M | 6.90M |
| Total Debt | 73.32K | 266.81K | 260.16K | 184.40K | 202.90K | 315.67K |
| Total Liabilities | 2.42M | 3.71M | 4.55M | 1.85M | 3.22M | 1.38M |
| Stockholders Equity | 3.77M | 7.07M | 822.01K | 6.25M | 9.60M | 6.55M |
Cash Flow | ||||||
| Free Cash Flow | -7.16M | -2.92M | -11.13M | -13.27M | -7.79M | -8.67M |
| Operating Cash Flow | -7.05M | -2.84M | -11.01M | -12.89M | -7.52M | -8.60M |
| Investing Cash Flow | -109.54K | -81.74K | -120.20K | 2.65M | -3.24M | -67.08K |
| Financing Cash Flow | 1.17M | 8.33M | 7.27M | 7.40M | 12.02M | 11.53M |
NeuroOne Medical Technologies Technical Analysis
Negative
2.16
Price Trends
2.09
Negative
3.05
Negative
3.82
Negative
Market Momentum
-0.11
Positive
41.08
Neutral
4.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 2.16 is above the 20-day moving average (MA) of 1.85, above the 50-day MA of 2.09, and below the 200-day MA of 3.82, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 41.08 is Neutral, neither overbought nor oversold. The STOCH value of 4.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeuroOne Medical Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $83.04M | -5.34 | 524.69% | ― | 33.45% | 0.24% | |
47 Neutral | $14.75M | -1.85 | -126.45% | ― | -1.67% | 7.34% | |
47 Neutral | $52.51M | -3.37 | -34.09% | ― | -53.40% | -1719.88% | |
39 Underperform | $277.44K | >-0.01 | -333.19% | ― | ― | 36.00% |
* Healthcare Sector Average
NMTC
NeuroOne Medical Technologies
1.69
-3.67
-68.48%
SRTS
Sensus Healthcare
3.16
-0.11
-3.36%
ECOR
Electrocore
9.08
4.00
78.74%
MODD
Modular Medical
2.82
-18.45
-86.74%
RBOT
Vicarious Surgical
0.04
-6.14
-99.29%
NeuroOne Medical Technologies Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
NeuroOne Advances StereoCED Toward Human Clinical Studies
Positive
Aug 27, 2026
On August 27, 2026, NeuroOne reported the successful completion of three large-animal procedures at the University of Minnesota using its next-generation StereoCED platform for robotic-assisted intracerebral drug delivery and electrophysiological ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
NeuroOne Expands At-The-Market Equity Offering Capacity
Positive
Jun 12, 2026
On December 21, 2022, NeuroOne Medical Technologies Corporation entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services, allowing the company to sell common stock from time to time through an at-the-market equity ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.